Imunon (IMNN) investor relations material

Pipeline overview and program updates

• IMNN-001, an IL-12 DNA plasmid therapy, is in a pivotal phase III trial (OVATION 3) for frontline ovarian cancer, following promising phase II results showing significant overall survival benefit over standard of care.

• The platform uses proprietary nanoparticle delivery for local administration, overcoming historic IL-12 toxicity issues.

• Enrollment in OVATION 3 is ahead of forecast, with 0.5 patients/site/month, targeting 500 patients and completion in Q1 2029.

• The platform is being explored for other cancers (gastric, pancreatic, colorectal, glioblastoma, mesothelioma) in partnership with the NCI.

Clinical trial data and development milestones

• Phase II trial showed a 14.7-month median overall survival improvement (45 vs. 30 months) and favorable safety profile, with no cytokine release syndrome or serious immune-related adverse events.

• MRD study shows lower minimal residual disease rates, higher ctDNA clearance, and improved progression-free survival in the experimental arm.

• Translational data confirm local IL-12 expression, immune activation, and remodeling of the tumor microenvironment.

• OVATION 3 is a randomized, controlled, frontline trial with OS as the primary endpoint and two planned interim analyses.

R&D strategy and innovation priorities

• Focus on frontline ovarian cancer, aiming to shift the standard of care by integrating immunotherapy with chemotherapy.

• Platform flexibility allows encoding of other immune agents for future pipeline expansion.

• Ongoing translational research includes spatial transcriptomics, single-cell RNA/TCR-seq, and biomarker-driven patient stratification.